NCT02845856View on ClinicalTrials.gov

Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 1, 2016

Primary Completion Date

July 1, 2017

Study Completion Date

July 1, 2019

Conditions
Recurrent Non-small Cell Lung Cancer
Interventions
DRUG

Cetuximab

400 mg/m2 IV over 120 minutes on day 1 of cycle 1 only, and 250 mg/m2 IV over 60 minutes weekly on ALL subsequent administrations

BIOLOGICAL

NK immunotherapy

For each procedure, 10 billion cells will be infused in 4 times

Trial Locations (1)

510000

Fuda cancer institute in Fuda cancer hospital, Guangzhou

All Listed Sponsors
collaborator

Shenzhen Hank Bioengineering Institute

OTHER

lead

Fuda Cancer Hospital, Guangzhou

OTHER

NCT02845856 - Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter